Evidence Paper Review

 Quick Explanation Copied

 Long Explanation

Core Evidence Base

This is a non-systematic narrative review of ~263 references, NIH-funded (HD085850, MH102890, MH099211, MH071537, MH094757, MH100122), with authors declaring no conflicts Review metadata and funding. Its strongest pillar is the meta-analysis it leans on: 20 studies confirmed elevated IL-1β, IL-6, TNF-α, and IFN-γ in PTSD, sustained after subgroup analyses excluding medicated patients and comorbid depression, with illness duration positively associated with inflammation Passos et al. PTSD inflammation meta-analysis. Yet the review honestly tabulates contradictory results (e.g., some studies report lower or null CRP in PTSD), attributing heterogeneity to sample size, comorbidities, and uncontrolled confounders.

Replication cohorts reinforce the peripheral signal: 163 male combat veterans showed elevated WBC (6.2 vs 5.5 ×10³/mL, p=0.004) and RBC (4.9 vs 4.7 ×10⁶/mL, p=0.003) in PTSD, correlating with symptom severity (platelets: r=0.30, p=0.007) Veteran blood cell count study, and an independent 61-veteran cohort replicated elevated composite pro-inflammatory scores Combat PTSD replication cohort.

Where the Review Is Strong — and Fragile

Strengths: breadth across cellular, epigenetic, and neurocircuitry levels; explicit causal humility — most data are cross-sectional, and the authors stress that prospective findings (pre-deployment CRP predicting PTSD) suggest inflammation may precede disorder rather than result from it Causal and confounder caveats. Fragilities: for GAD/PD/phobias the evidence is equivocal (mixed TNF-α, IL-4 findings; no studies of social or specific phobias), so DSM-5-wide claims rest largely on PTSD data. Behavioral confounders (sleep loss raising CRP/IL-6, smoking, obesity) are acknowledged but not disentangled. A mechanistic blind spot the review itself admits: the kynurenine pathway, though documented in depression, had no published PTSD data at the time. The proposed therapeutic angle (ACE-I/ARBs) rests on observational medication data, not trials ACE-I/ARB therapeutic proposal.

What Would Change the Verdict

Larger longitudinal studies showing no PTSD-inflammation association after controlling depression would falsify the central claim — notably, post-MI data show depressive symptoms substantially reshape (and can reverse) the PTSD–CRP/leptin relationships Post-MI PTSD depression-modified inflammation, and recovered women show normalized inflammation vs current-PTSD women PTSD recovery inflammation normalization.

 BGPT Paper Review

Study Novelty

First synthesis of inflammation across DSM-5 fear/anxiety disorders in 2016, extending the depression-inflammation literature to PTSD/GAD/PD; conceptually new framing though built from existing single-disorder findings.

Scientific Quality

Rigorous, balanced narrative review that tabulates null and contradictory results and cites the Passos meta-analysis; however, it is non-systematic, PTSD-heavy, and relies on cross-sectional evidence without pre-registered protocols.

Study Generality

Mechanistic framework (HPA axis, autonomic tone, NFκB, neurocircuitry) generalizes across disorders, but empirical support is largely PTSD-specific; GAD/PD/phobia sections remain thin.

Study Usefulness

Directed attention to inflammation as a biomarker and candidate target (ACE-I/ARBs, anti-inflammatory strategies) in psychiatry, shaping later prospective and treatment research.

Study Reproducibility

As a review it reproduces no data, but its claims are traceable to cited primary studies and one meta-analysis; the field's heterogeneity limits replication of any single association.

Explanatory Depth

Offers multi-level mechanistic chains (stress → FKBP5/GR resistance → cytokines → glutamate/kynurenine → amygdala/ACC/insula dysfunction) but several links rest on rodent or inflammation-challenge extrapolations.